Skip to content

Design, synthesis, biological evaluation and computational investigation of Thiadiazole Benzimidazole derivatives bearing a Chlorophyrimidine pharmacophore as potent CLK2 inhibitors and anticancer agents.

Oct 2026 · Bioorganic chemistry (Print) · Vol 183, pp. 110618 · 0 citations · 34 references
Medicine

Abstract

Cdc2-like kinase 2 (CLK2) has emerged as an attractive anticancer therapeutic target because of its crucial role in pre-mRNA splicing and tumor growth. Here, we designed and synthesized a novel series of thiadiazole-based benzimidazole derivatives 15a-l incorporating chloropyrimidine pharmacophore and evaluated for CLK2 inhibition and antiproliferative activity against HCT116 cells. The synthesized derivatives exhibited CLK2 inhibition potential ranged from 0.2332 nM to >50 nM, with 15i displaying the highest potency with IC50 of 0.2332 nM, followed by 15 l (0.3342 nM), 15 k (0.5648 nM), and 15 g (0.6453 nM), as compared to standard T-025 (IC50 = 1.0 nM). In antiproliferative assay, 15 l exhibited the highest activity against HCT116 cells with IC50 23.52 nM, followed by compounds 15 h (28.54 nM), 15i (29.17 nM), and 15 g (33.43 nM), demonstrating higher cellular potency than T-025 (IC50 = 42 nM). Structure activity relationship (SAR) analysis indicated that fluorinated aromatic substituents and certain heteroaryl moieties linked to a thiadiazole ring favored CLK2 inhibition, although biochemical and cellular activities were not directly proportional. Molecular docking and molecular dynamics simulations provided a structural rationale consistent with experimental results by revealing the favorable and stable binding interactions within the CLK2 ATP-binding pocket. Density functional theory (DFT) calculations and in silico ADMET predictions further supported favorable electronic properties, drug-likeness and low predicted toxicity of the synthesized compounds.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.